title: [Vasoactive effects of femostone in women with metabolic postmenopausal syndrome].
abstract: The metabolic postmenopausal syndrome (MPS) is characterized by a complex of metabolic disorders: lipid (76%), purin (56%), calcium-phosphorus (61%). There is also a rise in amplitude of spontaneous platelet aggregation (61%) and fibrinogen levels (78%). Clinically, these phenomena manifest in arterial hypertension and defective cerebral circulation. An estrogen-histogen drug femoston was tried for clinical effectiveness and tolerance in 40 females with MPS. Femoston was used in long-term regimen for 12 months. The response was observed in all the patients, all the above parameters underwent positive changes. The drug was well tolerated, side effects were moderate. No withdrawals occurred.
authors.forename: S B
authors.initials: SB
authors.lastname: Malichenko
authors.forename: E P
authors.initials: EP
authors.lastname: Amial'eva
authors.forename: L B
authors.initials: LB
authors.lastname: Lazebnik
mesh_terms: D002118:Calcium / Q000097:blood; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004394:Dydrogesterone / Q000627:therapeutic use*; D004958:Estradiol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008659:Metabolic Diseases / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D010758:Phosphorus / Q000097:blood; D010974:Platelet Aggregation; D017698:Postmenopause / Q000097:blood; D011687:Purines / Q000097:blood; D013577:Syndrome; D016896:Treatment Outcome; D014664:Vasodilation / Q000187:drug effects* / Q000502:physiology
chemical_list: D008055:Lipids; D011687:Purines; D010758:Phosphorus; D004958:Estradiol; D004394:Dydrogesterone; D002118:Calcium